Fecal Calprotectin Testing Market Size & Share, by Disease Type (Inflammatory Bowel Disease, Colorectal Cancer, Celiac Disease); Patient Type (Geriatric, Pediatric, Adult); End-user (Hospitals, Diagnostic Laboratories, Academics, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4060
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Fecal Calprotectin Testing Landscape

    • Exelixis Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Becton, Dickinson and Company
    • Abbexa Limited
    • Bioserv Diagnostics Gmbh
    • Epitope Diagnostics, Inc.
    • LifeSpan BioSciences, Inc.
    • RayBiotech, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Thermo Fisher Scientific to launch a new large-volume electroporation system for cell therapy developers to facilitate commercial manufacturing of clinical therapy systems.

  • Exelixis Inc. announced the successful results for Cabozantinib in combination with immunotherapies in patients with advanced colorectal cancer.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4060
  • Published Date: Mar 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of colorectal cancer and other gastrointestinal diseases is estimated to boost the market growth.

The market is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2023-2035.

Lack of researchers in the field of pathology coupled with the high cost associated with fecal calprotectin testing and low awareness level about the advantages are some of the factors that are estimated to hamper the expansion of the market size.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Exelixis Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, patient type, end-user, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying